Editor's note: Seeking Alpha is proud to welcome Dislocation Capital as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.I am an individual investor with over 7 years of experience investing in the market. I have a Masters In Marketing Research and Bachelors in Mechanical Engineering. I have worked in multiple roles across the CPG, Pharma, Data Analytics, ...

分组1 - Seeking Alpha welcomes Dislocation Capital as a new contributing analyst, encouraging individuals to share investment ideas for publication and potential earnings [1] 分组2 - An individual investor with over 7 years of market experience has a diverse background in various industries, focusing on multiple investment strategies to achieve capital and income growth [2] - The investor utilizes a wide range of investment vehicles including Common Shares, Preferred Shares, Baby Bonds, CEFs, ETFs, Convertibles, and Short Options, as well as alternative financial investments like Notes, P2P Lending, and Crowdsourced Real Estate [2] - The investor aims to replace their salary with a combination of income and capital drawdowns, aligning with the F.I.R.E movement for early retirement [2]

Galaxy Digital Inc. (NASDAQ: GLXY) CEO Mike Novogratz said in an interview aired on Tuesday that he’s not giving up on Bitcoin (CRYPTO: BTC) despite the negative sentiment, but cautioned against going overly bullish too soon.Novogratz Says More ‘Healing To Do’Speaking to SkyBridge Capital founder Anthony Scaramucci, Novogratz expressed confidence that Bitcoin has not yet seen its all-time high, though agreed that there’s more “healing to do.”“How we get momentum back in crypto pricing has always been about ...

Core Viewpoint - The article critiques the notion that AI is a bubble, emphasizing the potential for lucrative investments in the sector based on the author's extensive experience in investing and risk management [1]. Group 1 - The author, Bram de Haas, has 15 years of investing experience and over 5 years managing a Euro hedge fund, indicating a strong background in financial markets [1]. - The author utilizes risk management skills developed from a background as a professional poker player to identify investment opportunities in special situations [1].

Darden Restaurants (NYSE:DRI) stock is flashing a potential trend-following entry in late December after a sharp 2025 pullback. The core thesis is straightforward: the long-term uptrend looks intact, momentum indicators are turning, and fundamentals—paired with institutional positioning—create a credible path to market-beating total returns in 2026 if the stock clears nearby resistance. It allowed indicators, including the moving average convergence divergence (MACD) and stochastic, to reset, indicating a m ...

Core Viewpoint - Sanofi's tolebrutinib, an investigational treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS), has received a complete response letter (CRL) from the FDA, indicating a significant setback in its regulatory submission process [1][3]. Regulatory Update - The FDA's review of tolebrutinib is expected to extend beyond the previously set target action date of December 28, 2025, with further guidance anticipated by the end of Q1 2026 [2]. - Sanofi has submitted an expanded access protocol for tolebrutinib in response to an FDA request [2]. Company Response - Sanofi expressed disappointment regarding the FDA's decision, emphasizing the unmet medical need for addressing disability progression in MS and the previous breakthrough therapy designation awarded to tolebrutinib [3]. - The company remains committed to collaborating with the FDA to find a path forward for tolebrutinib [3]. Product Information - Tolebrutinib is designed as an oral, brain-penetrant Bruton's tyrosine kinase inhibitor targeting neuroinflammation, which is a key factor in disability progression in MS [6]. - The drug was provisionally approved in the UAE in July 2025 for treating nrSPMS and is under review in the EU and other regions [4]. Financial Considerations - Sanofi is conducting an impairment test on the intangible asset value of tolebrutinib, with results expected to be reported alongside Q4 and FY 2025 results in January 2026 [5]. - The outcome of this test will not affect the company's net income or earnings per share, and there is no change to the financial guidance for 2025 [5]. Commitment to Innovation - Tolebrutinib reflects Sanofi's dedication to developing innovative treatments for neurological diseases, aiming to transform the treatment landscape for conditions like MS and other neurodegenerative disorders [7].

Core Viewpoint - Elis has announced a share capital decrease through the cancellation of treasury shares, which is part of its ongoing strategy to optimize capital structure and enhance shareholder value [1]. Group 1: Share Capital Decrease - On December 23, 2025, the Management Board decided to reduce Elis's share capital by cancelling 4,705,107 treasury shares, which represents 1.98% of the total share capital [2]. - The treasury shares cancelled were repurchased under the Group's share buyback program, which was authorized by shareholders in previous meetings [3]. Group 2: New Share Capital Structure - Following the cancellation, Elis's new share capital is €232,848,588, divided into 232,848,588 shares with a par value of one euro each [4]. - After the capital decrease, Elis retains 239,759 treasury shares, which represent 0.10% of the share capital [4]. Group 3: Company Overview - Elis is a leader in circular services, providing rental-maintenance solutions optimized by traceability technologies across 31 countries [5]. - The company focuses on meeting customer needs related to protection, hygiene, and well-being while supporting environmental objectives [5].

Core Viewpoint - Sanofi's tolebrutinib, an investigational treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS), has received a complete response letter (CRL) from the FDA, indicating a significant setback in its regulatory approval process [1][3]. Regulatory Update - The FDA's review of tolebrutinib is expected to extend beyond the previously set target action date of December 28, 2025, with further guidance anticipated by the end of Q1 2026 [2]. - Sanofi has submitted an expanded access protocol for tolebrutinib in response to an FDA request [2]. Company Response - Sanofi expressed disappointment regarding the FDA's decision, emphasizing the unmet medical need for addressing disability progression in MS and the importance of considering expert and patient perspectives in the review process [3]. Product Background - Tolebrutinib is a brain-penetrant Bruton's tyrosine kinase inhibitor designed to target neuroinflammation, a key factor in disability progression in MS [6]. - The drug was provisionally approved in the UAE in July 2025 for treating nrSPMS and is under review in the EU and other regions [4]. Financial Considerations - Sanofi is conducting an impairment test on the intangible asset value of tolebrutinib, with results expected to be reported alongside Q4 and FY 2025 results in January 2026. This test will not impact the company's net income or financial guidance for 2025 [5]. Commitment to Innovation - Tolebrutinib reflects Sanofi's dedication to developing innovative treatments for neurological diseases, aiming to transform the treatment landscape for conditions like MS and other neuro-inflammatory disorders [7].

Investor Gary Black has shared his insight into Tesla Inc.'s (NASDAQ:TSLA) recent stock surge as the year draws to a close.‘I Love The Tesla Story,' Says Gary BlackSharing his thoughts on Tuesday on X, the investor called Tesla the "most profitable EV business model on the planet," and added that the company's Optimus production next year, scaled-up autonomous driving tech, as well as CEO Elon Musk's commitment, were positives for the company. "I love the $TSLA story," Black said.However, the investor share ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...